Michael E. Luggen

4.7k total citations · 2 hit papers
43 papers, 2.9k citations indexed

About

Michael E. Luggen is a scholar working on Rheumatology, Immunology and Pathology and Forensic Medicine. According to data from OpenAlex, Michael E. Luggen has authored 43 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Rheumatology, 14 papers in Immunology and 13 papers in Pathology and Forensic Medicine. Recurrent topics in Michael E. Luggen's work include Systemic Lupus Erythematosus Research (17 papers), Rheumatoid Arthritis Research and Therapies (15 papers) and Autoimmune and Inflammatory Disorders Research (11 papers). Michael E. Luggen is often cited by papers focused on Systemic Lupus Erythematosus Research (17 papers), Rheumatoid Arthritis Research and Therapies (15 papers) and Autoimmune and Inflammatory Disorders Research (11 papers). Michael E. Luggen collaborates with scholars based in United States, Germany and Austria. Michael E. Luggen's co-authors include Maxime Dougados, Mark C. Genovese, Isaac Nuamah, Jean‐Claude Becker, Richard Aranda, Michael Schiff, J. Box, Joel Kremer, David Hagerty and Yvonne Sherrer and has published in prestigious journals such as New England Journal of Medicine, JAMA and SHILAP Revista de lepidopterología.

In The Last Decade

Michael E. Luggen

42 papers receiving 2.8k citations

Hit Papers

Abatacept for Rheumatoid Arthritis Refractor... 1985 2026 1998 2012 2005 1985 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α Inhibition
    2005 920 citations Mark C. Genovese, Jean‐Claude Becker et al. New England Journal of Medicine profile →
  2. Comparison of low‐dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A Controlled Clinical Trial
    1985 382 citations H. James Williams, Robert F. Willkens et al. Arthritis & Rheumatism profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael E. Luggen United States 22 1.9k 883 762 497 482 43 2.9k
Arthur F. Kavanaugh United States 17 2.8k 1.5× 1.0k 1.2× 1.2k 1.6× 537 1.1× 469 1.0× 27 3.7k
Ken J. Bulpitt United States 21 1.9k 1.0× 778 0.9× 888 1.2× 326 0.7× 389 0.8× 33 2.9k
Alan Friedman United States 25 2.3k 1.2× 1.2k 1.3× 503 0.7× 213 0.4× 755 1.6× 75 3.3k
Serge Steinfeld Belgium 21 1.7k 0.9× 1.3k 1.5× 753 1.0× 218 0.4× 271 0.6× 52 3.4k
Doyt L. Conn United States 28 1.5k 0.8× 544 0.6× 344 0.5× 273 0.5× 597 1.2× 65 2.8k
Joseph Wajdula United States 21 2.7k 1.4× 1.1k 1.3× 1.2k 1.6× 479 1.0× 375 0.8× 35 3.4k
Jean‐Claude Becker United States 17 2.9k 1.5× 1.7k 1.9× 1.3k 1.7× 751 1.5× 629 1.3× 23 4.3k
Kristina Forslind Sweden 28 2.5k 1.3× 420 0.5× 688 0.9× 320 0.6× 373 0.8× 81 3.0k
Yiannis Ioannou United Kingdom 32 2.0k 1.0× 902 1.0× 1.1k 1.5× 210 0.4× 254 0.5× 95 3.5k
Cédric Lukas France 27 2.7k 1.4× 929 1.1× 877 1.2× 233 0.5× 349 0.7× 112 3.3k

Countries citing papers authored by Michael E. Luggen

Since Specialization
Citations

This map shows the geographic impact of Michael E. Luggen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael E. Luggen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael E. Luggen more than expected).

Fields of papers citing papers by Michael E. Luggen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael E. Luggen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael E. Luggen. The network helps show where Michael E. Luggen may publish in the future.

Co-authorship network of co-authors of Michael E. Luggen

This figure shows the co-authorship network connecting the top 25 collaborators of Michael E. Luggen. A scholar is included among the top collaborators of Michael E. Luggen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael E. Luggen. Michael E. Luggen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Feist, Eugen, Roy Fleischmann, Saeed Fatenejad, et al.. (2024). Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment. Annals of the Rheumatic Diseases. 83(11). 1454–1464. 3 indexed citations
2.
3.
4.
Nash, Peter, Michael E. Luggen, Luis R. Espinoza, et al.. (2020). SAT0431 PROPORTIONS OF PATIENTS ACHIEVING A MINIMAL DISEASE ACTIVITY STATE UPON TREATMENT WITH TILDRAKIZUMAB IN A PSORIATIC ARTHRITIS PHASE 2B STUDY. Annals of the Rheumatic Diseases. 79. 1171–1171. 1 indexed citations
5.
6.
Luggen, Michael E., Gaurav Gulati, Bin Zhang, Rohan Willis, & Emilio B. González. (2015). Non-criteria anti-phospholipid antibodies and cognitive impairment in SLE. Clinical Rheumatology. 35(1). 93–99. 4 indexed citations
7.
Genovese, Mark C., Michael Schiff, Michael E. Luggen, et al.. (2012). Longterm Safety and Efficacy of Abatacept Through 5 Years of Treatment in Patients with Rheumatoid Arthritis and an Inadequate Response to Tumor Necrosis Factor Inhibitor Therapy. The Journal of Rheumatology. 39(8). 1546–1554. 52 indexed citations
8.
Keystone, Edward, Joel M. Kremer, Anthony S. Russell, et al.. (2012). Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study. Annals of the Rheumatic Diseases. 71(6). 857–861. 43 indexed citations
9.
Brunner, Hermine I., et al.. (2011). Cognitive Dysfunction in Patients with Systemic Lupus Erythematosus: A Controlled Study. The Journal of Rheumatology. 38(6). 1020–1025. 16 indexed citations
10.
Taylor, Janalee, et al.. (2009). Monitoring Methotrexate Toxicity in Juvenile Idiopathic Arthritis. The Journal of Rheumatology. 36(12). 2813–2818. 21 indexed citations
11.
Wasko, Mary Chester, Helen B. Hubert, Vijaya Bharathi Lingala, et al.. (2007). Hydroxychloroquine and Risk of Diabetes in Patients With Rheumatoid Arthritis. JAMA. 298(2). 187–187. 196 indexed citations
12.
Genovese, Mark C., Jean‐Claude Becker, Michael Schiff, et al.. (2005). Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α Inhibition. New England Journal of Medicine. 353(11). 1114–1123. 920 indexed citations breakdown →
13.
Mould, Diane R., Charles B. Davis, Elisabeth A. Minthorn, et al.. (1999). A population pharmacokinetic-pharmacodynamic analysis of single doses of clenoliximab in patients with rheumatoid arthritis. Clinical Pharmacology & Therapeutics. 66(3). 246–257. 52 indexed citations
14.
15.
Clegg, Daniel O., H. James Williams, Joyce Z. Singer, et al.. (1991). Early undifferentiated connective tissue disease. II. The frequency of circulating antinuclear antibodies in patients with early rheumatic diseases.. PubMed. 18(9). 1340–3. 49 indexed citations
16.
Bendon, Robert W., Paul E. Hurtubise, Tariq Jamal Siddiqi, et al.. (1990). Prenatal Screening for Anticardiolipin Antibody. American Journal of Perinatology. 7(3). 245–250. 4 indexed citations
17.
Williams, H. James, John Ward, Stephen L. Dahl, et al.. (1988). A controlled trial comparing sulfasalazine, gold sodium thiomalate, and placebo in rheumatoid arthritis. Arthritis & Rheumatism. 31(6). 702–713. 89 indexed citations
18.
Thun, Michael J., Shiro Tanaka, Adam B. Smith, et al.. (1987). Morbidity from repetitive knee trauma in carpet and floor layers.. Occupational and Environmental Medicine. 44(9). 611–620. 50 indexed citations
19.
Williams, H. James, Daniel E. Furst, Stephen L. Dahl, et al.. (1985). Double‐blind, multicenter controlled trial comparing topical dimethyl sulfoxide and normal saline for treatment of hand ulcers in patients with systemic sclerosis. Arthritis & Rheumatism. 28(3). 308–314. 32 indexed citations
20.
Stewart, John, Michael E. Luggen, & Heinz Valtin. (1972). A computer model of the renal countercurrent system. Kidney International. 2(5). 253–263. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Arthur F. Kavanaugh Breakdown of academic impact, for papers by Ken J. Bulpitt Breakdown of academic impact, for papers by Alan Friedman Breakdown of academic impact, for papers by Serge Steinfeld Breakdown of academic impact, for papers by Doyt L. Conn Breakdown of academic impact, for papers by Joseph Wajdula Breakdown of academic impact, for papers by Jean‐Claude Becker Breakdown of academic impact, for papers by Kristina Forslind Breakdown of academic impact, for papers by Yiannis Ioannou Breakdown of academic impact, for papers by Cédric Lukas
Rankless by CCL
2026